EX-10.12



 Exhibit 10.12 

EMPLOYMENT AGREEMENT 

THIS AGREEMENT is effective April 23, 2015. 
  

			
	BY AND BETWEEN:		 KLOX TECHNOLOGIES INC., a corporation incorporated under the laws of Canada, herein represented by Dr. Lise Hebert, its President
and CEO, duly authorized as she so declares;
  
 (hereinafter referred to as the
“Corporation”)

		
	AND:		 Dr. Michel Cimon, M.D., M.P.H., domiciled and residing at 2874 rue des Andes, Saint Laurent, Quebec, H4R3G3;

 
 (hereinafter referred to as the “Executive”)


 WHEREAS the Corporation has retained the services of the Executive to act as its Vice President Clinical and Medical
Affairs for a start of employment date of May 4, 2015, and the Executive has accepted to offer such services to the Corporation; 
 WHEREAS the
Parties wish to set forth and confirm the terms and conditions of the Executive’s employment with the Corporation as Vice President Business Development and Alliance Management (the “Agreement”); 

NOW THEREFORE THE PARTIES HAVE AGREED TO THE FOLLOWING: 

ARTICLE 1 - DEFINITIONS 
 For the purposes
of this Agreement, or for the purposes of any notice or communication required hereunder, the words and expressions set out below shall have the following meaning: 
  

	1.1	“Board” shall mean the board of directors of the Corporation. 

  

	1.2	 “Business” shall mean, in relation to the Corporation, the business now and hereafter conducted by the Corporation up to the
termination of the Agreement, as well as any business the Corporation was in the process of developing at the time of termination of the Agreement. The Business currently conducted by the Corporation consists in developing, manufacturing and selling
products based on biophotonic therapy which combines the use of chemical chromophores with an enhancing gel or other formulation and an activating light source used in (i) oral health (including periodontitis, gingivitis











	 	
and whitening, brightening and curing products), (ii) dermatology (such as skin rejuvenation and acne and other dermatological treatment products) and (iii) tissue repair and wound
healing (either cosmetic, aesthetic or therapeutic products) and (iv) other human and animal and health or cosmetic applications . 

  

	1.3	“Confidential Information” means all confidential or proprietary information relating to the Corporation, such as, without limiting the generality of the foregoing, intellectual and industrial property,
including know-how, trade secrets, patents (including pending patent applications and undisclosed patents), confidential facts relating to the Business or the business and affairs of the Corporation, including, without limitation, unpublished or
undisclosed financial results and related records, lists of equipment or operations, lists of customers, needs and requirements of past, present and prospective customers, lists of suppliers, lists of personnel, policies and practices, methods of
operation, product and manufacturing methods and know-how, business plans, sales and accounting records, contracts, correspondence and all related documents and information, acquired by the Executive by any means whatsoever, in any form whatsoever
(whether it be verbal, written, machine readable or otherwise). This also includes any information received by the Corporation from any third party towards which the Corporation has an obligation of confidentiality. However, “Confidential
Information” shall not include information which: 

  

	 	(i)	is in the public domain, without any fault or responsibility on the Executive’s part; 

  

	 	(ii)	after disclosure, is lawfully received by the Executive from another Person who is lawfully in possession of such Confidential Information and such other Person was not restricted from disclosing the said information to
the Executive; 

  

	 	(iii)	is independently developed by the Executive through Persons who have not had access to, or knowledge of, the Confidential Information; or 


 

	 	(iv)	is approved by the Corporation for disclosure prior to its actual disclosure. 

  

	1.4	“Intellectual Property Rights” is defined as any intellectual or industrial property rights related to the products and proceeds of the Executive’s services hereunder, including, but not limited
to, all patents, inventions, discoveries, ideas (whether patentable or not), copyrightable material, trademarks, industrial and artistic works or designs, and any improvements thereon, derivative works, applications thereof or know-how related
thereto, and all registrations and applications for registration of the aforesaid intellectual property rights. 

  

	1.5	“Person” shall mean any individual or other entity possessed of juridical personality, including, without limitation, a corporation, company, cooperative, partnership, trust, unincorporated association,
affiliate or Governmental body. 

  

	1.6	“Parties” shall mean the Corporation and the Executive collectively, and a “Party” shall mean one of them individually. 


  
 - 2 - 








 ARTICLE 2 - EMPLOYMENT AND TERM 

 

	2.1	The employment of the Executive with the Corporation shall be continued and governed by the terms of this Agreement as of the date hereof. 


 

	2.2	This Agreement is concluded for an indefinite period. 

  

	2.3	The Corporation shall employ the Executive on a full-time basis and the Executive shall provide all of his full working time to the Corporation. 


ARTICLE 3 - DUTIES 
  

	3.1	The Executive shall serve the Corporation in such capacity or capacities and shall perform such duties and exercise such powers pertaining to the management and operation of the Corporation and its affiliates as may be
determined from time to time by the Corporation’s CEO consistent with the office of the Executive. Without limitation of the foregoing, the Executive shall occupy the office of Vice President Clinical and Medical Affairs of the Corporation and
its affiliates and, for the duration of this Agreement, the Executive shall: 

  

	 	(i)	Under the authority and supervision of the Corporation’s President, perform the duties normally allotted to Vice President Clinical and Medical Affairs, including without limitation, the duties set forth in
Schedule A and those duties that may reasonably be assigned to the Executive diligently, honestly and faithfully to the best of the Executive’s abilities and in the best interests of the Corporation; 


 

	 	(ii)	Use his best efforts to promote the interests and goodwill of the Corporation and its affiliates. 

  

	3.2	Except as otherwise agreed in writing with the Corporation, the Executive shall not engage in duties other than those provided for in the Agreement, nor be employed with respect, or in relation, to any Person other than
the Corporation without the prior written consent of the Corporation. 

  

	3.3	Nothing herein shall prevent the Executive from undertaking charitable, community or recreational activities which are not in conflict with obligations hereunder and for which the Executive is not remunerated.


 ARTICLE 4 - PLACE OF WORK 

The Executive’s duties shall be initially carried out and performed from the head office of the Corporation with frequent travel to clinical sites, and
national and international alliance partners as well as the Corporation’s affiliates. It is understood and acknowledged by the Executive that a condition of employment is frequent travel required in the performance of his duties hereunder or
that is essential to the interests of the Corporation and its affiliates. 

  
 - 3 - 








 ARTICLE 5 - REPORTING PROCEDURES 

The Executive shall report to the President and CEO. The Executive shall report fully on the affairs of the Corporation under his supervision and advise to
the best of his ability and in accordance with reasonable business standards on all matters that may arise from time to time during the term of his employment by the Corporation. 

ARTICLE 6 - REMUNERATION 
  

	6.1	Base Salary 

  

	 	(i)	The annual base salary payable to the Executive for his services hereunder shall be $250,000 payable in accordance with the Corporation’s pay policies, as amended from time to time, and subject to all applicable
deductions (the “Annual Base Salary”). 

  

	 	(ii)	Said Annual Base Salary shall be reviewed at each calendar year starting in 2016 to determine whether an increase thereof is appropriate in light of inflation. 


 

	6.2	Bonus 

 Following the end of each calendar year of employment, the Executive shall be eligible to receive
a cash bonus of up to twenty five percent (25%), except in respect of the fiscal 2015 year which will be at a rate of up to twenty percent cent (20%), of the of the Annual Base Salary paid to the Executive in the respective preceding year. The
amount of such cash bonuses shall depend upon the achievement of the Corporation of its corporate goals and objectives, the achievement of the Executive of the goals and objectives of his responsibility as well as other variables as deemed
appropriate by the Corporation. 
 ARTICLE 7 - GENERAL EXPENSES 

The Executive shall be reimbursed for all approved and reasonable out-of-pocket expenses actually and properly incurred by the Executive in performing his
responsibilities for the Corporation from time to time in connection with carrying out his duties hereunder and in compliance with the Corporation’s policies and practices in existence from time to time. For all such expenses the Executive
shall furnish to the Corporation expense reports on a timely basis including the originals of all invoices in respect of which the Executive seeks reimbursement. 

ARTICLE 8 - BENEFITS 
 The Executive shall
have the right to participate in benefit programs and/or plans granted to employees of the Corporation, the whole in accordance with the actual programs or plans that the Corporation may institute from time to time or as otherwise required under any
applicable law, including but not limited to a monthly car allowance of $1,000 per month payable via the payroll, as well as a group RRSP program whereby the Corporation will match the Executive’s subscription investment into a group RRSP plan
with a third part carrier of up to to 5% of his actively employed bi-monthly base salary paid after 3 months of active and continued service. The group medical and dental plan offered to employees will be available to the Executive’s
subscription on the first day of employment. 

  
 - 4 - 








 ARTICLE 9 - VACATION 

The Executive shall be entitled to 20 (twenty) days of paid vacation each full year of active employment during the term of this Agreement. In addition, the
Executive shall be entitled to all paid Holidays given by the Corporation to its employees generally or as otherwise required under any applicable law. 

ARTICLE 10 - TERMINATION 
  

	10.1	Termination For Cause 

 The Corporation may terminate the employment of the Executive “for
cause” at any time, without notice and without compensation. For the purposes of this Agreement and without limiting the generality of the foregoing, “For Cause” shall mean a “serious reason” and/or “for good and
sufficient cause” as those terms have been interpreted pursuant to the laws of Québec, and without limiting the generality of the foregoing, shall include: 
  

	 	(i)	The Executive’s wilful failure substantially to perform his duties and responsibilities to the Corporation or his deliberate violation of a Corporation policy; 


 

	 	(ii)	The commission by the Executive of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused, or is reasonably expected to result in, material injury to the Corporation;


  

	 	(iii)	The unauthorized use or disclosure by the Executive of any proprietary information or trade secrets of the Corporation or any other party to whom the Executive owes an obligation of nondisclosure as a result of his
relationship with the Corporation; or 

  

	 	(iv)	The willful breach by the Executive of any of his obligations under any written agreement or covenant with the Corporation, in each case after receiving written notification and being given an opportunity to cure any
such failure or breach. 

  

	10.2	Termination Without Cause 

 The Corporation may terminate this Agreement and the employment of the
Executive at any time, by providing 45 days’ prior notice of termination (the “Notice of Termination”). Should the Executive’s employment with the Corporation be terminated for any reason whatsoever other than For Cause or
as a result of an effective change of control of the Corporation and other than 

  
 - 5 - 








 
upon the Executive’s death, retirement at normal retirement age or should the Executive terminate his employment for Good Reason (as defined hereinafter), the Executive will be entitled to
the following severance benefits: 
  

	 	•	 	An amount equal to three (3) months of the Annual Base Salary payable plus one (1) month of annual base salary for each completed full year of active employment, all subject to a total maximum of twelve
(12) months of annual base salary in total (the “Severance Benefits”). The Executive understands and agrees that any performance, bonus or merit reviews that may be pending, in process, or “past due” will not be taken into
account or included in the severance pay. The Executive also agrees that in order to receive the Severance Benefits payment, he must sign a separation and release and discharge agreement within twenty (20) days of being notified of the
termination, indemnifying and holding the Corporation, its parent Company, and affiliates, directors, officers and others harmless 

 If the
termination without cause follows an effective change of control of the Corporation, then the Severance Benefits shall be payable in accordance with the Corporation’s pay policy over the severance period unless the Corporation is notified by
the Executive in writing within two (2) weeks of such termination that he elects that his Severance Benefits be payable as a lump sum payment, or a set of lump sum payments over a specified period of time, in which case this lump sum payment or
payments shall be payable within 10 days after such notification. If this termination without cause does not follow an effective change of control of the Corporation, then the Severance Benefits shall be payable in accordance with the
Corporation’s pay policy over the severance period. 
 For greater certainty, and notwithstanding any other provision in this agreement, the
parties agree that if the Executive’s position is restructured or changed for another senior management position within the Corporation, with equivalent base salary, bonus and all benefits, this shall not be interpreted as a constructive
dismissal and the Executive shall not have the right to seek the application of this section 10.2, but the provisions of this section shall continue to apply for the benefit of the Executive after this change of position within the
Corporation. 
  

	10.3	Definitions 

 For the purposes hereof, “Good Reason” shall mean:  

 

	 	•	 	without the Executive’s express written consent, the assignment to the Executive of any duties materially inconsistent with the Executive’s position and status with the Corporation; or 


 

	 	•	 	over the Executive’s objections, a substantial reduction of the Executive’s duties and responsibilities; or 

  

	 	•	 	a reduction by the Corporation of the Annual Base Salary or benefits; or a change in the city of the Executive’s employment by the Corporation or its successor; or 


 

	 	•	 	the failure by the Corporation to maintain the Executive’s participation in or entitlement to the same level of benefits made available to the Executive immediately prior to the change of control of the Corporation
at levels equivalent to those in effect prior to the change of control of the Corporation. 


  
 - 6 - 








 The Corporation agrees to cooperate with the Executive in structuring the payment of severance compensation in a
manner, at no additional cost to the Corporation, as shall be most attractive to the Executive from a tax standpoint. 
 It is understood that the Executive
shall not be required to mitigate the amount of any payment hereunder by seeking other employment or otherwise. 
  

	10.4	Termination Upon Disability 

 This Agreement may be immediately terminated by the Corporation, without
notice and without compensation, if the Executive becomes permanently disabled. The Executive shall be deemed to have become permanently disabled if, because of illness, physical or mental disability, or for other causes beyond the control of the
Executive, the Executive has been continuously unable or unwilling or has failed to perform the Executive’s duties for a total of 180 days within a period of eight (8) months, consecutive or not. 

 

	10.5	Death of the Executive 

 In the event of the death of the Executive during the term of this Agreement,
the Corporation undertakes to pay to the Executive’s estate an amount equal to six (6) months of Executive’s salary at the time of death. This amount shall be payable as a lump sum within two (2) months after the date of the
death. 
  

	10.6	Termination By Executive 

 Should the Executive decide to voluntarily terminate his employment hereunder
prior to the end of the term hereof, the Executive may terminate this Agreement and his employment hereunder upon not less than 30 days’ prior written notice to the Corporation. At any time after the Executive provides such notice, the
Corporation shall be free, at its sole discretion, to terminate the employment of the Executive immediately so long as it continues to pay all amounts owing as annual base salary and continue to provide the other benefits set out hereunder for the
balance of the notice period. 
  

	10.7	Fair and Reasonable 

 The parties hereto acknowledge that the pay in lieu of notice provisions in this
Article 10 are fair and reasonable and the Executive agrees that, upon any termination of this Agreement by the Corporation in compliance with sections 10.1 or 10.2 hereof, the Executive shall have no action, cause of action, claim, or demand
against the Corporation, or its officers, directors or employees as a consequence of such termination, and no amount shall be paid or owed to the Executive, pursuant to this Agreement, except for the amounts to which he is otherwise entitled under
this Agreement to the date of termination. 
  

	10.8	Return of Documents 

 In the event of the termination of the Executive’s employment with the
Corporation for any reason whatsoever, all documents, files, notes or other materials that may contain industrial secrets, Confidential Information, or any similar information, that are in the possession of the Executive at the time of termination,
whether they were created by the Executive or by any other Person, including any copies thereof, shall be immediately returned or remitted to the Corporation. 

  
 - 7 - 









	10.9	Stock Options 

 Following the start of the Executive’s employment on the effective date, it
will be recommended at the next Board of Directors Meeting that you be granted sixty thousand (60,000) stock options to purchase the equivalent number of Common shares of Klox Technologies Inc. pursuant and subject to the terms and conditions
of the approved Stock Option Plan. Stock options are granted by the Board of Directors at an exercise price equal to the fair value valuation price as determined by the Board of Directors at the date of grant and shall vest and be subject to the
terms and conditions of the approved Stock Option Plan and in effect from time to time. 
 Notwithstanding anything to the contrary in the approved Stock
Option Plan, all of the Executive’s Options shall vest and be available for exercise immediately prior to an effective change of control of the Corporation. 

ARTICLE 11 - NON-COMPETITION, NON-SOLICITATION, 

CONFIDENTIALITY AND OWNERSHIP OF INTELLECTUAL PROPERTY 
  

	11.1	Recognition: 

 The Executive hereby expressly recognizes that: 

 

	 	(i)	the Corporation is engaged in the Business, as defined herein; 

  

	 	(ii)	the services he will provide to the Corporation are special and unique; 

  

	 	(iii)	through his work with the Corporation, he will have access to industrial secrets and Confidential Information related to the Corporation; 


 

	 	(iv)	the Corporation does business on an international level; 

  

	 	(v)	the Corporation would not have concluded the present Agreement without the protections and undertakings contained in the present Article 11; and 


 

	 	(vi)	the protections and undertakings in the present Article 11 are necessary to preserve the legitimate interests of the Corporation. 

  

	11.2	Non-Competition 

 The Executive shall not, during the Executive’s employment and for the period
following the termination of the Executive’s employment set out below, directly or indirectly, in any way whatsoever, whether alone, through or in connection with any other Person, through or in connection with any other company, or in his
capacity of employee, mandatory, agent, consultant, advisor, director or shareholder, carry on, be engaged in or have any financial or other interest in or be otherwise commercially involved in any endeavour, activity or business, which is in whole
or in part in competition with the Business or provides similar competing services in all or in part of the territory set out below. 

  
 - 8 - 








 The Executive shall, however, not be in default under this Article by virtue of the Executive’s holding,
strictly for portfolio purposes and as a passive investor, no more than 5% of the issued and outstanding shares of, or any other interest in, any body corporate which is listed on any recognized stock exchange, the business of which body corporate
is the same as, is substantially similar to or is in competition with the Business. 
 Period of Non-Competition: The Executive’s
non-competition obligations set out above shall remain in effect for a period of 12 months following the termination of his employment for any reason, including his resignation. 

Territory: For the purposes of the Executive’s non-competition obligations set out above, the territory shall be Canada, United States, South and
Central America, Australia, Europe and Asia. 
  

	11.3	Solicitation of Employees 

 The Executive shall not, for a period of 12 months after the termination of
this Agreement, on the Executive’s own behalf or on behalf of any other Person, whether directly or indirectly, in any capacity whatsoever, alone, through or in connection with any Person: 

 

	 	(i)	employ, offer employment to or solicit the employment or engagement of or otherwise entice away from the employment of the Corporation any individual who is employed by the Corporation at the time of termination of this
Agreement or who was employed by the Corporation within the 12 months preceding the termination of this Agreement; or 

  

	 	(ii)	procure or assist any Person to employ, offer employment or solicit the employment or engagement of or otherwise entice away from the employment of the Corporation any individual who is employed by the Corporation at
the time of termination of this Agreement or who was employed by the Corporation within the 12 months preceding the termination of this Agreement. 

  

	11.4	Confidentiality 

 The Executive shall not, during his employment with the Corporation or any time
thereafter, directly or indirectly, use or disclose the Corporation’s Confidential Information to any Person whatsoever. The Executive acknowledges and agrees that the Confidential Information belongs exclusively to the Corporation and that the
confidentiality obligations hereunder must remain in effect for all time and must continue in full force and effect notwithstanding any violation or contravention, or any alleged violation or contravention of the present Agreement by the
Corporation. 
  

	11.5	Intellectual property 

 The Corporation shall be the sole owner of all the products and proceeds of the
Executive’s services hereunder, including, but not limited to, all materials, ideas, concepts, formats, 

  
 - 9 - 








 
suggestions, developments, writings, arrangements, packages, programs, mask work or patents, inventions, copyrightable material and other intellectual property and any improvements thereon or
derivative works or applications thereof and know-how related thereto (“Intellectual Property”) that the Executive may acquire, obtain, develop or create in connection with and during the term of the Executive’s employment by
the Corporation, free and clear of any claims by the Executive (or anyone claiming under the Executive) of any kind or character whatsoever. The Executive shall, at the request of the Corporation, execute such applications, assignments, certificates
or other instruments as the Corporation may from time to time deem necessary or desirable to evidence, establish, maintain, perfect, protect, enforce or defend its right, or title and interest in or to any such Intellectual Property, including,
without limitation, as may be deemed necessary by the Corporation to apply for and obtain copyrights or patents in the name of the Corporation. The Executive agrees to disclose immediately to the Corporation or any Person designated for such purpose
the acquisition, development or creation of any Intellectual Property and may under certain conditions be recognized as an inventor. The obligations of the Executive contained in this section 11.5 shall continue beyond the termination of his
employment hereunder, irrespective of the cause of termination, with respect to any of the Intellectual Property acquired, obtained, developed or created by the Executive during the term of employment hereunder. 

 

	11.6	Moral Rights 

 The Executive hereby irrevocably waives and agrees to waive all moral rights in and to the
Intellectual Property. 
  

	11.7	Recourse 

 The Executive recognized that any violation or anticipated violation of the obligations set
out in sections 11.2 to 11.6 inclusive hereof may result in material irreparable injury to the Corporation or its affiliates or subsidiaries for which there is no adequate remedy at law, that it will not be possible to measure damages for such
injuries precisely and that, in the event of such a breach or threat thereof, the Corporation shall be entitled to obtain any or all of a temporary restraining order and a preliminary or permanent injunction restraining the Executive from engaging
in activities prohibited by these sections or such other relief as may be required to enforce specifically any of the covenants in these sections. 

ARTICLE 12 - LEGAL ADVICE 
 The Executive
hereby represents and warrants to the Corporation and acknowledges and agrees that he had the opportunity to seek and was not prevented nor discouraged by the Corporation from seeking independent legal advice prior to the execution and delivery of
this Agreement and that, in the event that he did not avail himself of that opportunity prior to signing this Agreement, he did so voluntarily without any undue pressure and agrees that his failure to obtain independent legal advice shall not be
used by him as a defense to the enforcement of his obligations under this Agreement. 

  
 - 10 - 








 ARTICLE 13 - NOTICES 

Any notice or other communication required or permitted to be given hereunder shall be in writing and either delivered by hand, sent by email, or mailed by
prepaid registered mail. At any time other than during a general discontinuance of postal service due to strike, lock-out or otherwise, a notice so mailed shall be deemed to have been received five business days after the postmarked date thereof or,
if delivered by hand, shall be deemed to have been received at the time it is delivered. If there is a general discontinuance of postal service due to strike, lock-out or otherwise, a notice sent by prepaid registered mail shall be deemed to have
been received five business days after the resumption of postal service. Notice shall be addressed as follows: 
 To the Corporation:

 KLOX Technologies Inc. 

275 Armand Frappier 
 Laval,
Québec 
 H7V 4A7 

Email:           lhebert@kloxtechnologies.com 

Attention:     President and CEO 

To the Executive: 
 Michel
Cimon 
 2874 rue des Andes 

Saint Laurent, Quebec 
 H4R 3G3,
Canada 
 or at such other address as any of the parties may have previously indicated in writing in conformity with the foregoing. 

ARTICLE 14 - INTERPRETATION CLAUSES 
  

	14.1	Governing Law 

 This Agreement shall be construed in accordance with the intent of the
parties hereunder and governed by the laws of the Province of Québec and the laws of Canada where applicable. Any dispute whatsoever arising from the interpretation, application, or effect of this Agreement shall be referred to the courts
sitting in the District of Montreal. 
  

	14.2	Headings 

 The headings in this Agreement are for convenience only and shall not in any
way limit or be deemed to construe or interpret the terms and provisions of this Agreement. 

  
 - 11 - 









	14.3	Preamble 

 The preamble to this Agreement shall form an integral part hereof. 

 

	14.4	Additional Considerations 

 The parties shall sign such further and other documents,
cause such meetings to be held, resolutions passed and by-laws enacted, exercise their vote and influence, do and perform and cause to be done and performed such further and other acts and things as may be necessary or desirable in order to give
full effect to this agreement and every part thereof. 
  

	14.5	Severability 

 If, in any jurisdiction, any provision of this Agreement or its
application or any party or circumstances is restricted, prohibited or unenforceable, such provision shall, as to such jurisdiction, be ineffective only to the extent of such restriction, prohibition or unenforceability without invalidating the
remaining provisions hereof and without affecting the validity or enforceability of such provision in any other jurisdiction or its application to other parties or circumstances. 

 

	14.6	Waiver 

 The failure of either party at any time to require the performance by the other
party of any provision shall in no way affect the full right to require such performance at any time thereafter, nor shall a waiver by either party of any breach of the provisions be taken or held to be a waiver of any succeeding breach of such
provisions or as a waiver of the provision itself. The rights and recourses of the parties under this Agreement are cumulative and not alternative. 
  

	14.7	Assignment 

 Except as otherwise provided herein, the Executive shall not assign his
rights granted hereunder, in whole or in part, except with the prior written consent of the Corporation. 
  

	14.8	Successors and Assigns 

 This Agreement shall be binding upon and enure to the benefit of
the parties hereto and their respective successors and permitted assigns. Nothing herein, express or implied, is intended to confer upon any Person, other than the parties hereto and their respective successors and assigns, any rights, remedies,
obligations or liabilities under or by reason of this Agreement. 

  
 - 12 - 









	14.9	Counterparts 

 This Agreement may be executed in several counterparts, each of which so
executed shall be deemed to be an original, and such counterparts together shall constitute but one and the same instrument. 
  

	14.10	Declaration 

 Each party to the present declares and expressly acknowledges that the
provisions of this Agreement have been liberally negotiated between the parties. Each of the parties having read, signed and understood this Agreement, expressly renounces to invoke the nullity of any or all provisions for the purpose that such
provisions are abusive, incomprehensible and illegible. 
  

	14.11	Amendments 

 This Agreement may be modified or amended in whole or in part at the
parties’ discretion, however, any such modification shall only take effect when acknowledged in writing by all parties. 
  

	14.12	Entire Agreement 

 This Agreement and the schedules, if any, constitute the entire
agreement between the parties hereto and supersedes all prior agreements, representations, warranties, statements, promises, information, arrangements and understandings, whether oral or written, express or implied, with respect to the subject
matter hereof. 
  

	14.13	Currency 

 All references to monetary amounts in this Agreement shall be deemed to be
references to Canadian currency unless otherwise stipulated. 
  

	14.14	Language 

 The Parties confirm that they have agreed that this Agreement and all
documents relating hereto be drafted in English. Les Parties confirment qu’elles ont accepté que la présente convention, de même que tous les documents s’y rattachant, soient rédigés en anglais. 

[Signature page follows] 

  
 - 13 - 








 IN WITNESS WHEREOF the parties hereto have executed this Agreement, as of April 23, 2015. 

 

							
	 		 		 		KLOX TECHNOLOGIES INC.
				
	 /s/ Michel Cimon
		  		Per:		 /s/ Lise Hebert

	DR. MICHEL CIMON						 Lise Hebert
 President and CEO

				
					Per:		 /s/ Mariano Rodriguez

							 Mariano Rodriguez
 CFO



  
 - 14 - 








 SCHEDULE A 

POSITION:                       
                              Vice President Clinical and Medical Affairs 

PURPOSE OF THIS POSITION: STRATEGIZE AND OPERATIONALIZE THE MANAGEMENT
OF CLINICAL TRIALS AND MEDICAL AFFAIRS, ENSURE COMPLIANCE WITH ALL REGULATORY
AND GCP REQUIREMENTS AND TIMELY AND EFFICIENT EXECUTION OF CLINICAL TRIALS IN
SUPPORT OF ACHIEVING THE GLOBAL CORPORATE OBJECTIVES. 

RESPONSIBILITIES INCLUDE: 
  

	 	•	 	Responsible to strategize and oversee all the activities of the clinical and medical affairs team (trial design, clinical practices, clinical managements, clinical consultants and CROs) and participates with all aspects
of the clinical research process including: study design, protocol writing, preparation of informed consent forms (ICF) and case report forms (CRF), data management and statistical analysis plans, selection of study centers and investigator
meetings, negotiation of clinical trial agreements (CTA), efficient and rapid patient recruitment rates, monitoring, serious adverse event (SAE) reporting, report writing and publication/presentation of study results. 


 

	 	•	 	Participates with the development and review of scientific, technical documents (CTA/IND) including clinical trial protocols and amendments, investigator brochures (IB), annual safety reports, and common technical
documents. 

  

	 	•	 	Prepares, manages and presents study budgets, plans and project timelines to the President and CEO and the senior management team. 

  

	 	•	 	Provides assistance to the President & CEO, Business Development, Chief Commercial Officer (CCO), Chief Financial Officer (CFO) and Product Development teams with strategic development and tactical
implementation for programs in dermatology, oral health, wound healing and others. 

  

	 	•	 	Leads the efforts of advisory boards and understanding of the clinical implications of novel therapeutic targets and the evaluation of health economic components in the design of clinical trials. 


 

	 	•	 	Interacts effectively with R&D team members. 

  

	 	•	 	Leads and operationalizes the government and reimbursement strategies globally. 

  

	 	•	 	Create with the Regulatory Affairs team a worldwide strategy and activities for phamacovigilence and other regulatory matters. At a future date to be determined by the CEO, this position is also intended to oversee all
Regulatory Affairs personnel and items. 

  

	 	•	 	Represent KLOX Technologies on various committees involving external business partners (commercial agreements, joint ventures, etc.); 


 

	 	•	 	Oversee, in collaboration with other key internal / external collaborators, the development of pipeline products from laboratory (pre-clinical) to commercial stage; 


 

	 	•	 	Responsible for the top-line and bottom-line targets of the clinical and medical units; 

  

	 	•	 	Creation and management of relationships with key opinion leaders; 

  

	 	•	 	Development of strategies in collaboration with Executive Team, to ensure market share capture through market expansion, penetration and portfolio enhancement; 


 

	 	•	 	Timely and credible production and review of forecasts, reports and budgets as per Company’s requirements; 

  

	 	•	 	Coordination with and management of direct reports to optimize resources use and goals achievement; 

  

	 	•	 	When applicable and commercially available, innovative development of new campaigns, strategies, tactics and marketing techniques/vehicles; 


 

	 	•	 	People management: recruitment, performance reviews, coaching, feedback, development plans, etc. 


  
 - 15 -